ATLANTA, GA – – (Globe Newswire – August 7, 2026) – – A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune”) (NASDAQ: REPL). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (1) in connection with the Biologics License Application (“BLA”), the study design concerns previously communicated by the FDA were not addressed; (2) Replimune had submitted data from an early unplanned analysis from RP1-104, which included only 40 patients (10% of the planned enrollment of 400 patients); and (3) as a result, RPL-001-16 and RP1-104 both had deficiencies which were likely to cause the FDA to reject the BLA.

If you purchased shares of Replimune between October 20, 2025 and April 10, 2026, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/replimune-group/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is October 5, 2026.